Company Overview and News

 
IndusInd Bank, Bharat Financial trading flat even as CCI okays merger

2017-12-20 thehindubusinessline
Shares of IndusInd Bank and Bharat Financial Inclusion were trading flat even as the Competition Commission of India has approved the scheme of amalgamation between IndusInd Bank and Bharat Financial Inclusion.
Upvote Downvote

 
CCI clears IndusInd-Bharat Financial merger

2017-12-19 moneycontrol
Fair trade regulator CCI has approved the scheme of amalgamation between IndusInd Bank and Bharat Financial Inclusion.
Upvote Downvote

 
IndusInd, Bharat Fin merger: Premium paid for cost reduction, synergies and rural reach

2017-10-14 moneycontrol
IndusInd Bank on Saturday confirmed its acquisition of microfinance institution Bharat Financial Inclusion after over a month of exclusive merger arrangement.
Upvote Downvote

 
IndusInd Bank seals $2.4 billion deal to buy Bharat Financial Inclusion

2017-10-14 business-standard
India's IndusInd Bank Ltd agreed an all-share deal on Saturday to buy microlender Bharat Financial Inclusion Ltd for close to 155 billion rupees ($2.4 billion), boosting its presence in microfinance lending and rural banking.
Upvote Downvote

 
IndusInd reports a picture-perfect result even as buzz builds around Bharat Financial buy

2017-10-12 moneycontrol
IndusInd Bank delivered another quarter of predictable high quality earnings giving investors another reason to cheer at the beginning of the earnings season. A strong growth in low-cost deposits drove margin stability despite the bank stepping up its presence in the competitive corporate lending business. Its asset quality showed no signs of stress and fee income growth was decent. While the bank awaits meaningful recovery in the retail business in the second half of the fiscal, it is also gearing up to acquire Bharat Financial, which the management feels would be margin accretive from day one.
Upvote Downvote

 
This week in banking: IndusInd-Bharat Fin merger on cards, Bandhan Bank announces IPO plans

2017-09-16 moneycontrol
Banking sector this week started with two major announcements —IndusInd Bank announcing its exclusive merger talks with microfinance lender Bharat Financial Inclusion and Bandhan Bank gearing up for its IPO (initial public offering).
Upvote Downvote

 
Banking sector this week: IndusInd-Bharat Fin merger on cards, Bandhan Bank announces IPO plans

2017-09-16 moneycontrol
Banking sector this week started with two major announcements —IndusInd Bank announcing its exclusive merger talks with microfinance lender Bharat Financial Inclusion and Bandhan Bank gearing up for its IPO (initial public offering).
Upvote Downvote

 
IndusInd Will Discuss $2.2 Billion Bharat Financial Deal - Bloomberg

2017-09-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Bharat Financial: CIMB Bank cuts stake

2017-07-27 thehindubusinessline
CIMB Bank Berhad on Thursday sold 18 lakh shares of Bharat Financial Inclusion through a bulk deal at an average price of ₹820.32, NSE data reveals. The number of shares sold represents 1.3 per cent of the total paid-up shares of Bharat Financial, formerly SKS Microfinance. CIMB Bank Berhad held 2.35 per cent stake as on June 30. The name(s) of the buyer(s) could not be immediately known. Shares of BFIL may remain focus.
Upvote Downvote

 
Bharat Financial posts Rs37 crore loss in Q1

2017-07-26 livemint
Bharat Financial’s total revenue for the first quarter jumped nearly by 12% to Rs463.1 crore against Rs414.1 crore in the first quarter of FY17
Upvote Downvote

 
Bharat Financial: Direct assignment continues

2017-06-16 thehindubusinessline
Bharat Financial Inclusion (formerly SKS Microfinance) on Friday assigned a pool of receivables of an aggregate value of ₹539.67 crore to one of the largest public sector banks on direct assignment basis in accordance with the guidelines prescribed by the Reserve Bank of India.
Upvote Downvote

 
Broker's call

2017-06-15 thehindubusinessline
Our ‘Overweight’ view on Bharat Financial Inclusion (formerly SKS Microfinance) has been premised on our assumption that asset quality indicators are improving and the worst is known in terms of recognition and provisioning. Our view was that in the coming quarters, investor focus will shift to growth as write-offs are through.
Upvote Downvote

 
Bharat Financial to use 2 lakh kirana stores as service sites

2017-06-14 moneycontrol
Expanding its footprint across the length and breadth of the country, micro-finance lender Bharat Financial Inclusion will bring around 2 lakh Kirana stores to cater as service points with the digital imprint.
Upvote Downvote

 
Route One Fund buys stake in Bharat Financial for Rs 99 cr

2017-05-15 moneycontrol
Route One Fund I, LP today bought 0.88 per cent stake in Bharat Financial Inclusion for nearly Rs 99 crore, through an open market transaction.
Upvote Downvote

 
Bharat Financial reports Rs 235 cr Q4 loss

2017-05-01 business-standard
Hyderabad-based microfinance lender Bharat Financial Inclusion has reported a net loss of Rs 235 crore in the January-March quarter of the previous financial year, while it earned a net profit of Rs 84.47 crore in the same quarter a year ago.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...